Anzeige
Mehr »
Login
Sonntag, 12.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
572 Leser
Artikel bewerten:
(2)

Cannabis Sativa, Inc.: Cannabis Sativa Acquires Majority Stake in Contract Manufacturing Company GK Manufacturing

Finanznachrichten News

MESQUITE, NV / ACCESSWIRE / February 20, 2020 / Cannabis Sativa, Inc. (OTCQB:CBDS) announced today that it has acquired a 51% interest in GK Manufacturing and Packaging, Inc. ("GK Manufacturing") in a cash and stock deal.

GK Manufacturing is a newly formed Southern California contract manufacturing, co-packing and white label company, producing a wide range of highest quality, lab-tested CBD products including edibles, tinctures, drinks and topicals. The acquisition includes multiple brands such as the well-established Ganja Juice brand (ganja-juice.com) and the Murray & Rocco's CBD infused pet line. GK Manufacturing has pending nationwide and global sales contracts with companies in the US, UK, France and Spain. "We are excited to acquire a majority interest in a company that has strong co-packing and white label opportunities in the CBD industry. The multitude of new concepts and brand ideas under development by GK Manufacturing and CBDS will help to drive sales in the coming periods. The acquisition positions the companies in a good place in the booming CBD marketplace" said President David Tobias

GK Manufacturing plans to move into expanded facilities in Los Angeles county in Q2 of 2020. "All indicators show continuing strong growth in the CBD market in 2020 and beyond," said Tobias. "We look for increased revenues from the co-packing operations in the larger facility, as well as increased market share for the entire GK portfolio and a re-launch of the Cannabis Sativa proprietary brands including "hi", White Rabbit, Wild Earth Naturals and Virgin Mary Jane". The Ganja Juice brand, winner of numerous High Times and Cannabis Cup awards, will continue as a main focus.

About Cannabis Sativa, Inc.:

Cannabis Sativa, Inc. ("CBDS") is engaged in the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. CBDS licenses the "hi" and "White Rabbit" brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, a U.S. Patent for a marijuana lozenge, and operates subsidiaries including: PrestoDoctor® (https://prestodoctor.com), GK Manufacturing and Packaging, Inc. (https://ganja-juice.com/), Wild Earth Naturals® (https://wildearthnaturals.com), and iBudtender (https://ibudtender.com). The Company is the official licensee for Virgin Mary Jane Brand (https://virginmaryjanebrand.com). In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.

Forward-Looking Statements:

This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact Information:

Corporate (702) 762-3123
Mailing Address: PO Box 1602, Mesquite, NV 89024
https://www.cannabissativainc.com

SOURCE: Cannabis Sativa, Inc.



View source version on accesswire.com:
https://www.accesswire.com/577051/Cannabis-Sativa-Acquires-Majority-Stake-in-Contract-Manufacturing-Company-GK-Manufacturing

© 2020 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.